Extraordinary General Meeting of Shareholders

February 19th, 2018

Forward looking statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including but not limited to, statements regarding our strategy, future operations, future pre-clinical and clinical trial plans and related timing of trials and results, research and development, future financial position, future revenues, projected costs, prospects, therapeutic potential of our products, plans and objectives of management, are forward-looking statements. The words "aim," "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this presentation reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those that may be described in greater detail in the annual report filed on Form 20-F for the year ended December 31, 2016 that we have filed with the U.S. Securities and Exchange Commission (the "SEC") and any subsequent filings we have made with the SEC. We have included important factors in the cautionary statements included in that annual report, particularly in the Risk Factors section, and subsequent filings with the SEC that we believe could cause actual results or events to differ materially from the forward-looking statements that we make.

1. Opening of the EGM

Dinko Valerio, Chairman of the Supervisory Board

Agenda

1. Opening of the EGM
2. Business update

Voting items:

3. **Renewal of the delegation to the Management Board of the authority (i) to issue ordinary shares, (ii) to grant rights to subscribe for such shares and (iii) to limit and exclude pre-emption rights**
4. **Amendment articles of association**

5. Questions
6. Closing of the EGM

2. Discussion Item

Business update

Daniel de Boer, Chief Executive Officer


ProQR®
CREATING
MEDICINES
for patients
in need

Forward looking statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including but not limited to, statements regarding our strategy, future operations, future pre-clinical and clinical trial plans and related timing of trials and results, research and development, future financial position, future revenues, projected costs, prospects, therapeutic potential of our product candidates, plans and objectives of management, are forward-looking statements. The words "aim," "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this presentation reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those that may be described in greater detail in the annual report filed on Form 20-F for the year ended December 31, 2016 that we have filed with the U.S. Securities and Exchange Commission (the "SEC") and any subsequent filings we have made with the SEC. We have included important factors in the cautionary statements included in that annual report, particularly in the Risk Factors section, and subsequent filings with the SEC that we believe could cause actual results or events to differ materially from the forward-looking statements that we make.

Agenda

- Brief introduction
- Lookback 2017
  - Completion of second clinical trial for QR-010 in CF
  - Start clinical trial QR-110 for LCA10
  - Completion preparations for start of DEB trial
- Looking forward to 2018
  - Partnership(s)
  - Clinical data readouts in LCA10, DEB
  - Start clinical trial Usher syndrome

ProQR RNA medicine platform

ProQR RNA medicine platform



ProQR RNA medicine platform



ProQR RNA medicine platform

Healthy



Disease



ProQR RNA medicine platform



ProQR development pipeline



Strong team with proven track record

Management team

Daniel de Boer*
Chief Executive Officer

David Rodman
Chief Development Strategy Officer

Gerard Platenburg*
Chief Innovation Officer

Smital Shah
Chief Financial Officer

René Beukema
Chief Corp. Development Officer & General Counsel

Robert Cornelisse
Chief People & Organization

Supervisory board

Dinko Valerio*
Chairman

James Shannon

Alison Lawton

Paul Baart

Antoine Papiernik

Former supervisory board member

Henri Termeer*

* *Founding team*

QR-010 for F508del CF update

- Completed 2 clinical trials with positive data in CF patients
- Competitive landscape evolved
- Completed end of Phase 1 meetings with FDA and EMA
  - Agreement to move forward with a 12-week study in CF patients based on clinical and non-clinical data to date
  - Agreement on weekly inhaled dosing in the proposed dose range of 6.25mg to 12.5mg
  - Potential trial outline in US and EU
    - CFQ-R accepted as primary end point in US
    - LCI and CFQ-R as endpoints in the EU
    - Trial will include patients 12 and older
    - 12 week study with go/no go interim look at 4 weeks
- Start of a Phase 2 trial is pending a potential partnership

QR-110 for LCA10 update

- Started dosing patients in phase 1/2 clinical trial
  - Twelve p.Cys998X LCA10 patients; adults and children (≥6yrs)
  - 4 Intravitreal injections in one eye over 1 year
  - Participating sites: major sites in EU (UGhent) and US (UPenn, UIowa)
  - Primary endpoints: Safety, tolerability
  - Secondary endpoints: Pharmacokinetics, FST, mobility testing, visual acuity, OCT, PRO, ERG, nystagmus tracking, pupilometry)
- Orphan drug designation in EU and US
- FDA Fast-track designation
- 6 month treatment data in 2018, 12 month treatment data in 2019
- Recent advancement in field provides guidance for development

QR-421 for Usher syndrome

- Strong in vitro and in vivo PoC
- Phase 1/2 trial to start at YE 2018, with initial and full data readout in H1 2019
  - Intravitreal Injection of “worst eye” only
  - Contralateral eye and subject’s baseline as controls
  - Primary endpoints: Safety, tolerability and pharmacokinetics
  - Secondary endpoints: OCT: Photoreceptor layer thickness (focus on OS layer) starting at 2w, Visual Acuity, Visual Field, Full field ERG
- Several other ophthalmic programs in pipeline

QR-313 for dystrophic epidermolysis bullosa

- Completed IND enabling studies
- Phase 1/2 safety & tolerability trial in DEB patients to start in H1 2018, initial data readout in 2018
  - **Part A:**
    - 6-10 DEB patients with exon 73 mutations
    - Open label, single wound treatment 28 days
    - Primary endpoints: Safety, tolerability and pharmacokinetics
    - Pharmacokinetic endpoints: molecular PoC on exon skip, wound healing
  - **Part B:**
    - 6-10 DEB patients with exon 73 mutations
    - Placebo controlled, multiple wound (within patient placebo control), 28 days treatment
    - Primary endpoints: Safety, tolerability and pharmacokinetics
    - Pharmacodynamic endpoints: molecular PoC on exon skip and anchoring fibrils, wound healing
- Orphan drug designation in US and EU
- Start clinical trial early 2018, Part A data in 2018, Part B data in 2019

Amylon Therapeutics

CNS focused spin-off company

- In September 2017 ProQR spun out Amylon Therapeutics BV with a financing round funded by a group of external investors
- ProQR incubated the activities of Amylon since 2015
- Amylon aims to develop RNA therapeutics for CNS indications
- The initial focus of Amylon is on its development program AT-010 for HCHWA-D, a brain disease caused by a mutation in beta-amyloid leading to stroke in mid-adulthood
- Ultra-genetics approach for small genetic disorders with global potential and expansion possibility to CAA
- ProQR retained a majority shareholding in the company after spin-off

Collaboration with Galapagos NV on Fibrosis

Galápagos

- Collaboration announced on January 8th combining Galapagos' strength in Fibrosis with ProQR's RNA technology platform
- Applying ProQR's proprietary Axiomer RNA editing technology to novel Fibrosis targets selected by Galapagos
- Collaboration aims to validate novel Fibrosis targets and generate new therapeutic molecules
- This is ProQR's first industry collaboration validating the Axiomer platform technology
- Pioneering ProQR's RNA technology in yet another therapeutic area

ProQR development pipeline



ProQR since 2012

Facts and figures

- Based in Leiden, the Netherlands
- 140 employees (30 nationalities)
- 18 fully owned patent families and 6 licenses from academia
- 2014 IPO NASDAQ: PRQR
- Shares outstanding : ~32 million (+ ~4.5 million treasury shares)
- Cash position (end Q3 2017): € 39.7M
  - Raised approximately $20 million in Q4
- Projected cash runway: H2 2019

3. Voting Item

Delegation to the Management Board of the authority (i) to issue ordinary shares, (ii) to grant rights to subscribe for such shares and (iii) to limit and exclude pre-emption rights

Authorization to issue shares

Proposed authorization of Management Board:

a) To issue ordinary shares for general purposes and/or for mergers, demergers, acquisitions and other strategic transactions and alliances (or a combination thereof) up to 30% of the Company's issued share capital,
plus for issuance under stock option plans up to 15% of the Company's issued share capital (minus any treasury shares),

b) To grant rights to subscribe for ordinary shares as described under (a)

c) To limit or exclude the pre-emptive rights of holders of ordinary shares

- Valid for a period of 5 years from today
- Includes the authority to determine the price and further terms and conditions of any such share issuance or grant
- Subject to approval of the Supervisory Board

4. Voting Item

Amendment of articles of association

Amendment of articles of association

Proposed amendments:

- To increase authorized share capital from 37.5M to 90M ordinary shares
- To delete the requirement of a deed for the issuance of shares

5. Questions & Answers

6. Closing of the EGM

ProQR®

IT'S IN OUR RNA